Although further studies must be performed, this finding is highly significant as medical treatments do not exist for EFE and the novel application of this readily available drug can potentially limit EFE formation and promote better clinical outcomes.
← all excerpts
Abnormal Flow Conditions Promote Endocardial Fibroelastosis Via Endothelial-to-Mesenchymal Transition, Which Is Responsive to Losartan Treatment.
1
—
—